Drug and pharmaceutical recalls
354 federal recalls in the last 12 months. Federal recalls for prescription drugs, OTC medications, supplements, and pharmaceuticals. Sourced from the FDA and translated into plain English.
Recent recalls
Page 2 of 12- Abirtega abiraterone acetate recalled for failed weight uniformity
Hikma Pharmaceuticals is recalling Abirtega (abiraterone acetate) 250 mg tablets due to failed weight uniformity specifications. Lot 3047 (expiring July 2027) does not meet quality standards. The issue was identified during quality testing; no injuries have been reported.
ModerateFDAOct 23, 2026Hikma Pharmaceuticals
- Safecor Health metoclopramide tablets recalled for co-mingling
Safecor Health is recalling specific batches of metoclopramide 5 mg tablets manufactured for Teva Pharmaceuticals due to co-mingled tablets in the bottles. Co-mingling means tablets from different batches or products may have been mixed together. The affected lot is 3116509 with an expiry date of 07/31/2027.
ModerateFDAOct 23, 2026Safecor Health
- Glenmark abiraterone acetate tablets recalled for labeling problem
Glenmark Pharmaceuticals is recalling Abiraterone Acetate Tablets USP 500 mg in 60-count bottles due to a labeling defect. The affected lot (13250135, expiring 11/2027) was distributed nationwide. No injuries have been reported.
ModerateFDAOct 23, 2026Glenmark
- Ritedose Formoterol Fumarate inhalation solution recalled for impurity concerns
Ritedose Pharmaceuticals recalled one lot of Formoterol Fumarate Inhalation Solution (20mcg/2mL) because it failed quality testing for impurities and degradation. The affected lot (25BL0, expiring 02/28/2027) was distributed nationwide. No injuries have been reported.
ModerateFDAOct 23, 2026Ritedose
- Wedgewood Pharmacy veterinary medications recalled for potential potency issues
Wedgewood Pharmacy is recalling certain compounded veterinary medications shipped between February and October 2026 because lab testing data was unreliable, meaning some products may be weaker or stronger than intended. The affected medications include powders, pastes, oral liquids, injectables, and topical products for companion, equine, exotic, zoo, and aquatic animals. Wedgewood discovered the issue through its own quality checks and has received 98 complaints, including 7 serious ones.
ModerateFDAOct 21, 2026Wedgewood Pharmacy
- Par Health dexmedetomidine injection recalled for particulate matter
Par Health USA's Dexmedetomidine HCl injection vials contain unwanted particulate matter, identified as cellulose or stopper material. The contamination affects two specific lots distributed nationwide. This is a prescription medication used during anesthesia and sedation.
SeriousFDAOct 21, 2026Paragon 28
- American Health Packaging metoclopramide recalled for foreign tablets
American Health Packaging distributed metoclopramide 5 mg tablets that contained foreign tablets or capsules mixed in with the correct medication. The contamination was found in two lot numbers distributed nationwide. No injuries have been reported.
ModerateFDAOct 21, 2026American Health Packaging
- Houston Rx tirzepatide and sermorelin vials recalled for sterility concerns
Houston Rx is recalling two injectable products, a tirzepatide/niacinamide 2 mL vial and a sermorelin 10 mL vial, because the company cannot assure they are sterile. The recall covers 71 vials distributed nationwide in the USA, and the FDA has reported no injuries.
ModerateFDAOct 21, 2026Houston Rx2 products
- Zydus Hydrocortisone Sodium Succinate injection recalled for impurity concerns
Zydus Pharmaceuticals is recalling specific lots of Hydrocortisone Sodium Succinate for Injection because the drug failed quality testing for impurities and degradation. The affected lots (LB00047A and LB00048A, expiring 03/2028) were distributed nationwide. No injuries have been reported.
ModerateFDAOct 21, 2026Zydus
- Teva metoclopramide tablets recalled for foreign tablets or capsules
Teva Pharmaceuticals discovered that some bottles of Metoclopramide 5 mg tablets contain foreign tablets or capsules mixed in with the correct medication. The contamination was found in specific lots distributed nationwide. No injuries have been reported.
ModerateFDAOct 21, 2026Teva
- WAP Sensual Enhancement Capsules recalled for undeclared drugs
WAP Sensual Enhancement Capsules were sold without FDA approval and contain three undeclared prescription medications: sildenafil, tadalafil, and flibanserin. These are potent drugs that require a doctor's prescription and can cause serious health problems, especially in people taking other medications or with certain medical conditions.
SeriousFDAOct 20, 2026Erotic Enhancers
- Right Value Drug Stores testosterone cypionate recalled for sterility risk
Right Value Drug Stores LLC is recalling compounded testosterone cypionate injection (200 mg/mL) in 5 mL and 30 mL vials due to lack of sterility assurance. The affected vials were distributed nationwide to medical offices. No injuries have been reported.
ModerateFDAOct 19, 2026Right Value Drug Stores LLC
- Barbie, Hot Wheels and more toothpaste recalled for manufacturing issues
Ashtel Studios Inc. of Ontario, California is recalling 17 fluoride toothpaste products nationwide because they were made in ways that did not meet FDA manufacturing standards. The products are sold under the Barbie, Hot Wheels, Crayola and My Little Pony names, plus the Brush Buddies, evo, ARU and BB brands. No injuries have been reported.
ModerateFDAOct 19, 2026PRITAM INTERNATIONAL PRIVATE LIMITED17 products
- Pfizer Levoxyl 175 mcg tablets recalled for reduced potency
Pfizer is recalling specific lots of Levoxyl (levothyroxine sodium) 175 mcg tablets because stability testing found the drug potency fell below required specifications. This means some tablets may contain less active medication than labeled. The recall affects 134 bottles with lot number 24W07, expiring 11/30/2026.
ModerateFDAOct 16, 2026Pfizer2 products
- Hepalink Heparin Sodium Injection recalled for sterility concerns
Hepalink USA is recalling Heparin Sodium Injection (5,000 USP Units/mL) due to lack of assurance that the product is sterile. The affected multidose vials have lot number CU03232A with an expiration date of January 31, 2028. This product is used in hospitals and medical settings.
ModerateFDAOct 16, 2026Techdow
- Viatris telmisartan and amlodipine tablets recalled for potential superpotency
Certain lots of Telmisartan and Amlodipine 40mg/5mg tablets manufactured by Mylan Pharmaceuticals (Viatris) may contain higher-than-specified amounts of Telmisartan, the blood pressure-lowering active ingredient. The affected lots were distributed nationwide. No injuries have been reported.
ModerateFDAOct 16, 2026Viatris
- Ascend amlodipine and olmesartan tablets recalled for dissolution failure
Ascend Laboratories is recalling one lot of amlodipine and olmesartan medoxomil combination tablets (10mg/40mg) because they do not dissolve properly in the body. This means the medication may not work as intended. The affected lot was distributed nationwide.
ModerateFDAOct 16, 2026Ascend Laboratories
- Orbi 20 and Omni Gold creams recalled for mercury contamination
DANALVIG LLC is recalling two skin whitening creams, Orbi 20 Whitening Cream and Omni Gold Anti-Marks Cream Extra Brightening, sold nationwide through eBay. FDA analysis found the products contain mercury, and both are made by White Gold International in Lahore, Pakistan. No injuries have been reported.
SeriousFDAOct 14, 2026DANALVIG LLC2 products
- Apothecary Pharma tirzepatide and NAD+ injections recalled over sterility
Apothecary Pharma is recalling two sterile injection vials because the company cannot assure they are sterile. The recall covers 22 vials of Tirzepatide Injection 18 mg/mL (4 mL multi-dose vial) and 1 vial of Apothecary NAD+ Injection 200 mg/mL (6 mL multi-dose vial), distributed nationwide. No injuries have been reported.
ModerateFDAOct 14, 2026Apothecary Pharma2 products
- Taro and Northstar Rx tretinoin cream recalled for impurities
Sun Pharmaceutical is recalling three tretinoin cream USP 0.05% products, sold in 45 g and 20 g tubes under the Taro and Northstar Rx names. The cream failed the FDA's impurity and degradation standards. No injuries have been reported.
ModerateFDAOct 14, 2026Sun Pharmaceutical3 products
- Carolina Infusion compounded injectables recalled for sterility risk
Carolina Infusion LLC of Ridgeland, SC, is recalling 16 compounded injectable products sold as tirzepatide, semaglutide, semaglutide/cyanocobalamin, tirzepatide/cyanocobalamin, sermorelin, Quad-Mix, and Tri-MIX. The company cannot assure that the products are sterile, which relates to the bacteriostatic water used in the formulation and the processing equipment. No injuries have been reported.
ModerateFDAOct 14, 2026Carolina Infusion16 products
- J&J IMAAVY injection recalled for particulate matter
A single lot of IMAAVY (nipocalimab-aahu) injection contains particulate matter that should not be present in the medication. This affects 49 vials distributed in Ohio. The contamination was detected before the medication reached patients.
ModerateFDAOct 14, 2026Johnson & Johnson
- Cipla USA fosfomycin granules recalled for failed impurity specifications
Cipla USA is recalling one lot of Fosfomycin Tromethamine Granules for Oral Solution due to failed quality testing for impurities and degradation. The affected lot (5KA0405, expiring 12/31/2026) was distributed nationwide. No injuries have been reported.
ModerateFDAOct 14, 2026Cipla
- Preferred Pharmaceuticals Lidocaine Ointment recalled for content uniformity failure
Preferred Pharmaceuticals' Lidocaine Ointment USP 5% (generic Xylocaine) in 50 g jars failed to meet content uniformity specifications, meaning the active ingredient may not be evenly distributed throughout the product. This affects four specific lots with expiration dates of April 30, 2027. No injuries have been reported.
ModerateFDAOct 14, 2026Preferred Pharmaceuticals
- BioSpectra Tris/Tromethamine API recalled for stability failure
BioSpectra, Inc. is recalling one lot of Tris/Tromethamine, USP, GMP, API Grade manufactured at its Bangor, Pennsylvania facility. The affected lot failed stability testing specifications required for pharmaceutical-grade active ingredients.
ModerateFDAOct 14, 2026BioSpectra
- Best Choice, LEADER eye drops and more recalled for sterility
K.C. Pharmaceuticals is recalling eight sterile eye drop products sold nationwide because they may not be sterile. The products are sold under the Best Choice, Equaline, Good Sense, LEADER, exchange select and Crocodile Tears names. No injuries have been reported.
SeriousFDAOct 14, 2026K.C. Pharmaceuticals8 products
- Centric Compounding vitamin injections recalled for contamination
Centric Compounding of Houston, Texas, is recalling three sterile vitamin products sold as Tri-Immune Boost, Glutathione 200 mg/mL and Multidose Myers Cocktail vials. Test results found bacterial endotoxin levels outside acceptable limits. No injuries have been reported.
SeriousFDAOct 14, 2026Centric Compounding4 products
Par Pharmaceutical Brevital Sodium recalled for particulate matterPar Pharmaceutical is recalling two lots of Brevital Sodium 500 mg/vial, an injectable anesthetic used in hospitals, because they contain tiny cellulose particles. These particles could potentially cause serious blood vessel blockages or clotting if injected. No adverse events have been reported so far.
SeriousFDAOct 8, 2026Par Health
- Rugby Benzoyl Peroxide Wash recalled for microbial contamination
A batch of benzoyl peroxide wash distributed by Rugby Laboratories has been found to contain microbial contamination. The affected product is a 5% benzoyl peroxide topical wash in a 5 fl oz bottle, lot #0525-02-345, expiring 02/2027, distributed in Illinois only.
ModerateFDAOct 7, 2026SV Labs2 products
- Apotex paroxetine ER tablets recalled for failed dissolution
Apotex Corp. is recalling Paroxetine Extended-Release Tablets 37.5mg (Lot# TY9495, Exp Date 05/2027) because they failed to meet dissolution specifications. This means the tablets may not break down properly in the body, affecting how much medicine is absorbed.
ModerateFDAOct 7, 2026Apotex